Immunomodulatory medicines for multiple sclerosis: Progress and prospects

Drug Development Research

Volumn 72, Issue 8, 2011, Pages 664-673

  Palmer, Alan M ^a  

^a MS Therapeutics Ltd   (United Kingdom)

Author keywords

4 1 integrin; interferon; anti inflammatory drugs; blood brain barrier; clinical trial; copaxone; disease modifying drugs; human studies; immunomodulatory medicines; neuroinflammation; neuroprotection; neuroprotective drugs; pharmacotherapy

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; LAQUINIMOD; LEMTRADA; MITOXANTRONE; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

DISEASE COURSE; DRUG MARKETING; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

EID: 83655191789     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20476     Document Type: Review

References (78)

1. + T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line. J Leukoc Biol 86: 1049-1063.
2. bright natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103: 5941-5946.
3. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R,. 2009. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66: 483-489.
4. Bill R, Doring A, Deutsch U, Engelhardt B,. 2011. PSGL-1 is dispensible for the development of active experimental autoimmune encephalomyelitis in SJL/J mice. J Neuroimmunol 232: 207-208.
5. Carlow DA, Gossens K, Naus S, Veerman KM, Seo W, Ziltener HJ,. 2009. PSGL-1 function in immunity and steady state homeostasis. Immunol Rev 230: 75-96.
6. Casetta I, Iuliano G, Filippini G,. 2007. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev, CD003982.
7. Claussen MC, Korn T,. 2011. Immune mechanisms of new therapeutic strategies in MS-Teriflunomide. Clin Immunol, in press.
8. Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L,. 2008. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev, CD005278.
9. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
10. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK,. 2008. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786-1801.
11. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, et al. 2011. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10: 338-348.
12. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, et al. 2008. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085-2092. (Pubitemid 351842581)
13. Compston A, Coles A,. 2008. Multiple sclerosis. Lancet 372: 1502-1517.
14. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G,. 1996. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46: 1607-1612.
15. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Hamlett A, Miret M, Weiner J, et al. 2011. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 17: 578-593.
16. D'Souza M, Kappos L, Czaplinski A,. 2008. Reconsidering clinical outcomes in multiple sclerosis: relapses, impairment, disability and beyond. J Neurol Sci 274: 76-79.
17. Davenport RJ, Munday JR,. 2007. Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12: 569-576. (Pubitemid 47044874)
18. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A,. 2010. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 81: 907-912.
19. Engelhardt B,. 2008. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 274: 23-26.
20. Engelhardt B, Kappos L,. 2008. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 5: 16-22. (Pubitemid 350261811)
21. Engelhardt B, Ransohoff RM,. 2005. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26: 485-495. (Pubitemid 41139258)
22. Engelhardt B, Vestweber D, Hallmann R, Schulz M,. 1997. E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 90: 4459-4472. (Pubitemid 27508451)
23. Etemadifar M, Janghorbani M, Shaygannejad V,. 2007. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol 254: 1723-1728.
24. Filippi M, Agosta F,. 2010. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 31: 770-788.
25. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH,. 2008. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131: 808-817. (Pubitemid 351294716)
26. Fisniku LK, Altmann DR, Cercignani M, Tozer DJ, Chard DT, Jackson JS, Miszkiel KA, Schmierer K, Thompson AJ, Miller DH,. 2009. Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler 15: 668-677.
27. Fox RJ, Bethoux F, Goldman MD, Cohen JA,. 2006. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med 73: 91-102.
28. Frohman EM, Racke MK, Raine CS,. 2006. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354: 942-955.
29. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Chang P, Hamlett A, et al. 2010. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416-426.
30. Hellwig K, Gold R,. 2011. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol.
31. Hilas O, Patel PN, Lam S,. 2010. Disease modifying agents for multiple sclerosis. Open Neurol J 4: 15-24.
32. Huppert J, Closhen D, Croxford A, White R, Kulig P, Pietrowski E, Bechmann I, Becher B, Luhmann HJ, Waisman A, Kuhlmann CR,. 2010. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J 24: 1023-1034.
33. Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, et al. 2010. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133: 2232-2247.
34. Kala M, Miravalle A, Vollmer T,. 2011. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol 235: 9-17.
35. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P,. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401.
36. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A,. 2007. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13: 1173-1175. (Pubitemid 47530640)
37. Kerfoot SM, Kubes P,. 2002. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 169: 1000-1006. (Pubitemid 34753459)
38. Kerfoot SM, Norman MU, Lapointe BM, Bonder CS, Zbytnuik L, Kubes P,. 2006. Reevaluation of P-selectin and alpha 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis. J Immunol 176: 6225-6234.
39. Koch-Henriksen N, Sorensen PS,. 2010. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 9: 520-532.
40. Koch M, Kingwell E, Rieckmann P, Tremlett H,. 2010. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 81: 1039-1043.
41. Kurtzke JF,. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452. (Pubitemid 14237132)
42. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H,. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128: 2705-2712. (Pubitemid 41552953)
43. La Mantia L, Munari LM, Lovati R,. 2010. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev CD004678.
44. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ,. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240. (Pubitemid 40189432)
45. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G,. 2010. Evidence for a two-stage disability progression in multiple sclerosis. Brain 133: 1900-1913.
46. Lublin FD, Reingold SC,. 1996. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
47. Martinelli Boneschi F, Rovaris M, Capra R, Comi G,. 2005. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev CD002127.
48. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson T, et al. 2007. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204: 2363-2372. (Pubitemid 47529322)
49. Miller DH, Leary SM,. 2007. Primary-progressive multiple sclerosis. Lancet Neurol 6: 903-912. (Pubitemid 47405002)
50. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R,. 2006. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900. (Pubitemid 43739766)
51. Osmers I, Bullard DC, Barnum SR,. 2005. PSGL-1 is not required for development of experimental autoimmune encephalomyelitis. J Neuroimmunol 166: 193-196. (Pubitemid 41074669)
52. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA, Sobel RA, Robinson WH, Steinman L,. 2007. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 448: 474-479. (Pubitemid 47123511)
53. Palmer AM,. 2009. Pharmacotherapy for multiple sclerosis: progress and prospects. Curr Opin Invest Drugs 10: 407-417.
54. Palmer AM,. 2010a. The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiol Dis 37: 3-12.
55. Palmer AM,. 2010b. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Invest Drugs 11: 1313-1323.
56. Palmer AM,. 2011. The role of the blood brain barrier in neurodegenerative disorders and their treatment. J Alzheimers Dis 24: 643-656.
57. Pandey K, Lublin FD,. 2009. Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal. Curr Treat Options Neurol 11: 193-202.
58. Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE,. 2011. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 17: 970-979.
59. Pirko I, Johnson AJ, Lohrey AK, Chen Y, Ying J,. 2009. Deep gray matter T2 hypointensity correlates with disability in a murine model of MS. J Neurol Sci 282: 34-38.
60. Plosker GL,. 2011. Interferon-beta-1b: a review of its use in multiple sclerosis. CNS Drugs 25: 67-88.
61. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
62. Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L, Thompson AJ, Wolinsky JS,. 2009. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology 73: 552-559.
63. Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, Filippini G,. 2001. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev CD002002.
64. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, Comabella M, Montalban X,. 2006. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59: 344-352. (Pubitemid 43202488)
65. Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E,. 2010. Interferon Beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev, CD006643.
66. Rowan WC, Hale G, Tite JP, Brett SJ,. 1995. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 7: 69-77.
67. Rudick RA, Goelz SE,. 2011. Beta-interferon for multiple sclerosis. Exp Cell Res 317: 1301-1311.
68. Schrempf W, Ziemssen T,. 2007. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6: 469-475. (Pubitemid 47069973)
69. Schweingruber N, Reichardt SD, Luhder F, Reichardt HM,. 2011. Mechanisms of glucocorticoids in the control of neuroinflammation. J Neuroendocrinol, in press.
70. Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A,. 2010. Drug class review: disease-modifying drugs for multiple sclerosis: final update 1. Report www.ncbi.nlm.nih.gov/books/NBK50570/.
71. Soon D, Altmann DR, Fernando KT, Giovannoni G, Barkhof F, Polman CH, O'Connor P, Gray B, Panzara M, Miller DH,. 2007. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. J Neurol 254: 306-314. (Pubitemid 46399190)
72. Sperandio M,. 2006. Selectins and glycosyltransferases in leukocyte rolling in vivo. FEBS J 273: 4377-4389. (Pubitemid 44401589)
73. Stoll G, Kleinschnitz C, Meuth SG, Braeuninger S, Ip CW, Wessig C, Nolte I, Bendszus M,. 2009. Transient widespread blood-brain barrier alterations after cerebral photothrombosis as revealed by gadofluorine M-enhanced magnetic resonance imaging. J Cereb Blood Flow Metab 29: 331-341.
74. Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe J, Evangelou N,. 2009. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 132: 1190-1199.
75. Trojano M,. 2011. Multiple sclerosis: the evolving diagnostic criteria for multiple sclerosis. Nat Rev Neurol 7: 251-252.
76. Uddin S, Platanias LC,. 2004. Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol 37: 635-641. (Pubitemid 40221522)
77. + regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979. (Pubitemid 38481088)
78. Vos CM, Geurts JJ, Montagne L, van Haastert ES, Bo L, van der Valk P, Barkhof F, de Vries HE,. 2005. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 20: 953-960. (Pubitemid 41619370)